New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
|Videos|February 20, 2014
EZH2 as a Potential Target in Diffuse Large B Cell Lymphoma
Author(s)Ari Melnick, MD
Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B cell lymphoma
Advertisement
Ari Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B cell lymphoma (DLBCL).
Clinical Pearls:
- EZH2 is an epigenetic modifier protein that forms part of the so-called polycomb complex 2 that was found to be highly expressed in DLBCL
- Studies have shown that EZH2 functions to suppress checkpoints that stops cells from dividing
- EZH2 is frequently mutated in the GCB-type DLBCL tumors and in follicular lymphomas, supercharging the protein
- The mutation adds three methyl groups to the tails of histone 3 lysine 27, which causes the repression of proliferation checkpoint regulatory genes and genes involved in the differentiation of B cells
- The supercharged EZH2 blocks the ability of germinal center B cells to differentiate, causing the cells to continue to divide
Advertisement
Related to this article
Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia at risk of thrombotic events.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5